Indobufen Noninferior to Aspirin for DAPT After PCI: OPTION

Antiplatelet agent indobufen was noninferior to aspirin in combination with clopidogrel after coronary intervention on both efficacy and safety outcomes, with less mostly minor bleeding.

Related Keywords

Germany ,Zhongshan ,Anhui ,China ,Shanghai ,United States ,Munich ,Bayern ,California ,Irvine ,American ,Dipti Itchhaporia ,Eric Sheila Samson ,University Of California ,American Heart Association ,German Heart Center Munich ,Academic Research Consortium ,Vascular Institute ,American College Of Cardiology ,Drug Administration ,American Heart Association Scientific Sessions ,Hangzhou Zhhongmei Huadong Pharmaceutical Co Ltd ,Fudan University ,Shanghai Clinical Research Center ,National Medical Products Administration ,Zhongshan Hospital ,Bleeding Academic Research Consortium ,Stefanie Sch ,Medscape Cardiology ,Sheila Samson ,Hoag Heart ,American College ,Interventional Medicine ,Clinical Research Special Fund ,Zhongshan Hospital Fudan ,Heart Association , ,Aspirin ,Cv ,Ardiovascular ,Drug Eluting Stent ,Atherosclerotic Heart Disease ,Therosclerotic Cardiovascular Disease ,Oronary Heart Disease ,Schemic Heart Disease ,Myocardial Infarction ,Antiplatelet Agent ,Hospitals ,Ischemic Stroke ,Cox 1 Inhibitor ,Yclooxygenase 1 Inhibitor ,Percutaneous Coronary Intervention ,